The first generation of biotech companies were based on either proteins or antibodies. Amgen Inc. chose the former, but has now begun making moves to get it into the latter field. As AMGN looks beyond proteins, it has formed development agreements for human monoclonal antibodies with both providers of the technology, Abgenix Inc. and Medarex Inc.

Last week's deal with MEDX follows an April agreement with ABGX (see B2 and BioCentury, May 3).